Skip to main content

Townsend Adam J.'s Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Dec 5, 2023

Accession no.
0001127602-23-028964
Filed
Dec 5, 2023
Trade date
Dec 1, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.69M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Townsend Adam J.CIK 0001773588Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2023Common StockMOption exerciseAcquired+110,000$15.09+$1,659,900186,407Direct
Dec 1, 2023Common StockSSaleDisposed−67,557$60.50−$4,087,198.5118,850Direct
Dec 1, 2023Common StockSSaleDisposed−42,443$61.31−$2,602,180.3376,407Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 1, 2023Common StockMOption exerciseDisposed−110,000$0.00$0172,500Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)